Long Term Outcomes in Patients With Non‐Infectious Mixed Cryoglobulinemic Vasculitis
- 24 February 2026
- journal article
- Published by Wiley in American Journal of Hematology
- Vol. 101 (5) , 1108-1113
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)Clinical Rheumatology, 2022
- Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literatureAutoimmunity Reviews, 2022
- Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot studyJournal of Autoimmunity, 2021
- Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic reviewAutoimmunity Reviews, 2015
- A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitisArthritis & Rheumatism, 2011
- A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus–associated cryoglobulinemic vasculitisArthritis & Rheumatism, 2011
- Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registryArthritis Care & Research, 2010
- Increased Risks of Lymphoma and Death Among Patients With Non–Hepatitis C Virus–Related Mixed CryoglobulinemiaArchives of internal medicine (1960), 2006
- Incidence and Characteristics of Non-Hodgkin Lymphomas in a Multicenter Case File of Patients With Hepatitis C Virus–Related Symptomatic Mixed CryoglobulinemiasArchives of internal medicine (1960), 2005
- Biologic and clinical significance of cryoglobulinsThe American Journal of Medicine, 1974